Taro Pharmaceutical Industries (TARO) Set to Announce Quarterly Earnings on Wednesday

Taro Pharmaceutical Industries (NYSE:TARO) will be issuing its quarterly earnings data after the market closes on Wednesday, February 7th.

Taro Pharmaceutical Industries (NYSE:TARO) last announced its quarterly earnings data on Tuesday, November 7th. The company reported $1.30 EPS for the quarter. Taro Pharmaceutical Industries had a net margin of 44.07% and a return on equity of 15.66%.

Taro Pharmaceutical Industries (TARO) opened at $103.14 on Wednesday. The company has a market cap of $4,156.97, a PE ratio of 12.70 and a beta of 0.63. Taro Pharmaceutical Industries has a 52-week low of $94.00 and a 52-week high of $128.46.

Separately, BidaskClub lowered shares of Taro Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Thursday, October 12th.

WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/31/taro-pharmaceutical-industries-taro-set-to-announce-quarterly-earnings-on-wednesday.html.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Earnings History for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply